Republic of Korea vs Thailand: Share of E. coli infections resistant to cephalosporins
Republic of Korea
38.8%
in 2022
Thailand
33.8%
in 2022
Republic of Korea rank
21st
Thailand rank
23rd
Share of E. coli infections resistant to cephalosporins over time
- Republic of Korea
- Thailand
How they compare
Republic of Korea currently reports 38.8% against 33.8% in Thailand, a difference of 5.0%.
That makes Republic of Korea's figure about 1.2 times Thailand's.
The two have swapped places 3 times across 7 shared years of data; in 2016 it was Thailand ahead.
Republic of Korea ranks 21st and Thailand ranks 23rd of 46 countries.
Across the 2 decades both report, Republic of Korea averaged higher in 1 and Thailand in 1.
Head to head by decade
| Decade | Republic of Korea | Thailand | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 35.9% | 38.9% | 3.1% | Thailand |
| 2020s | 37.7% | 36.9% | 0.9% | Republic of Korea |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher share of e. coli infections resistant to cephalosporins, Republic of Korea or Thailand?
- Republic of Korea, at 38.8% against 33.8% in Thailand as of 2022.
- What is the difference in share of e. coli infections resistant to cephalosporins between Republic of Korea and Thailand?
- 5.0%, with Republic of Korea ahead.
- How many years of comparable data are there for Republic of Korea and Thailand?
- 7 years are reported by both, from 2016 to 2022.
- How do Republic of Korea and Thailand rank globally for share of e. coli infections resistant to cephalosporins?
- Republic of Korea ranks 21st and Thailand ranks 23rd of 46 countries.
- Where does this data come from?
- World Health Organization – processed by Our World in Data, published as Share of E. coli infections resistant to cephalosporins. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Percentage of bloodstream infection due to Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested (%).